The H131R polymorphism of FCGR2A gene encoding FcγRIIA, (whose expression is restricted to myeloid cells), is associated with patient responses to rituximab (lymphoma), cetuximab (colon cancer), and trastuzumab (breast cancer). This evidence concerns the gene FCGR2A and colonic neoplasm.